☆ 4.3 Article

Long-term effectiveness of advanced hybrid closed loop in children and adolescents with type 1 diabetes

PEDIATRIC DIABETES (2022)

Related references

Note: Only part of the references are listed.
Article Endocrinology & Metabolism

Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes

Anders L. Carlson et al.

Summary: This trial assessed the safety and effectiveness of an advanced hybrid closed-loop system in adolescents and adults with type 1 diabetes. The results demonstrate that this system is safe and allows patients to achieve recommended glycemic targets, with the potential to further optimize glycemia.

DIABETES TECHNOLOGY & THERAPEUTICS (2022)

Add to Collection
Article Endocrinology & Metabolism

Real-World Performance of the MiniMed™ 780G System: First Report of Outcomes from 4120 Users

Julien Da Silva et al.

Summary: The preliminary performance evaluation of the MiniMed 780G system in real-world settings shows that most users are able to achieve good glycemic control and minimize hypoglycemia, indicating the effectiveness of the system.

DIABETES TECHNOLOGY & THERAPEUTICS (2022)

Add to Collection
Article Endocrinology & Metabolism

Closed-Loop Insulin Therapy Improves Glycemic Control in Adolescents and Young Adults: Outcomes from the International Diabetes Closed-Loop Trial

Elvira Isganaitis et al.

Summary: The study shows that the closed-loop control (CLC) insulin delivery system can significantly improve time in range (TIR), reduce time spent in high blood glucose levels, decrease hypoglycemia rates, and potentially improve glycemic outcomes in adolescents and young adults with type 1 diabetes.

DIABETES TECHNOLOGY & THERAPEUTICS (2021)

Add to Collection
Article Endocrinology & Metabolism

Real-world performance of the MiniMed™ 670G system in Europe

Julien Da Silva et al.

Summary: The study evaluated the real-world performance of the MiniMed 670G system in individuals with diabetes in Europe. Results showed that most users achieved a time in range of over 70% and an average GMI of less than 7% while using the automated insulin delivery system, regardless of their pre-Auto Mode GMI levels.

DIABETES OBESITY & METABOLISM (2021)

Add to Collection
Article Endocrinology & Metabolism

Rapid Improvement in Time in Range After the Implementation of an Advanced Hybrid Closed-Loop System in Adolescents and Adults with Type 1 Diabetes

Pilar Isabel Beato-Vibora et al.

Summary: The study aimed to evaluate the impact of AHCL system implementation on glycemic control in patients with type 1 diabetes. Results showed that after using the AHCL system, patients had significantly increased TIR, reduced time in hyperglycemia, and no significant change in hypoglycemia time.

DIABETES TECHNOLOGY & THERAPEUTICS (2021)

Add to Collection
Article Endocrinology & Metabolism

Safety Evaluation of the MiniMed 670G System in Children 7-13 Years of Age with Type 1 Diabetes

Gregory P. Forlenza et al.

DIABETES TECHNOLOGY & THERAPEUTICS (2019)

Add to Collection
Article Endocrinology & Metabolism

State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018

Nicole C. Foster et al.

DIABETES TECHNOLOGY & THERAPEUTICS (2019)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.